INTRODUCTION
Varicose vein (VV) is defined as dilated, elongated, tortuous superficial vein of leg having reflux with a prevalence rate of 50-55% in females and 40-50% in males. Reflux may be due to incompetent valves at saphenofemoral junction (SFJ) or in the main trunk/axis of great saphenous vein (GSV) or short saphenous vein (SSV) or due to incompetent perforators as well. Often bunches of varicosities are found on lateral or medial aspect of leg due to incompetent tributaries. Main trunk or main axis of incompetent superficial vein of leg is treated by endovenous thermal ablation, foam sclerotherapy, crossectomy and stripping of GSV.
Various treatment modalities for treatment of varicosities of tributaries are mini-phlebectomy, liquid sclerosant, foam sclerotherapy and Trivex. Various sclerosants used in VV treatment are sodium tetra-decyl sulphate (STD), polidocanol, ethanolamine oleate, sodium morhuate, hypertonic saline, phenol etc.
Out of these STD and polidocanol (POL) are safe and most commonly used. [2] [3] [4] [5] [6] In this study we have compared early outcomes in patients having any one of these two sclerosants viz. STD and POL in the treatment of varicosities of tributaries of GSV and SSV. Patients having incompetent SFJ /SPJ who were admitted were followed in OPD post treatment and discharge.
METHODS
Patients having incompetent SFJ was treated by Endovenous Laser ablation (1470 nm, Biolitec) or Ligation and cutting of all three tributaries (crossectomy) and SFJ ligation and stripping of GSV up to knee followed by treatment of tributaries varicosities in OPD after one week. Three percent sclerosants (Inj Setrol having 3% STD for Group A or Inj Asklerol having 3% polidocanol for Group B) were easily available and these were diluted to 1.0% (2ml 3 % sclerosant in a ampoule was diluted by adding 4 ml Normal Saline).
Maximum 2 ampoules (120mg) were used in a single sitting. Foam was prepared by having 1% sclerosant in one 20 ml Luer Lock syringe and 4 times room air in another syringe. Both syringes were connected to tri-way stopcock and by 20-22 times to and fro motion of both syringes foam was prepared. Post therapy patients were evaluated immediately for various outcomes like allergy, visual disturbances, headache and anaphylactic shock. Other outcomes like pain, hyperpigmentation, skin necrosis Figure 5 , DVT, embolism was documented on first day and after 4 weeks of sclerotherapy.
RESULTS
In this study total 56 patients were enrolled having varicosities of tributaries; n=26 patients in Group A and n=30 Patients in Group B. Result of n=6 patients in each group could not be evaluated due to loss of follow up. Finally results of n=20 patients in Group A and n=24 patients in Group B were evaluated.
In Group A, out of 20 patients, 17 patients were treated for SFJ incompetency and 03 patients for SPJ incompetency with SFJ incompetency. These patients having superficial varicosities were treated by 1% STD foam sclerotherapy in OPD Table 1 .
In Group B, 23 patients had only SFJ incompetency and one had both SFJ and SPJ incompetency. These n=24 patients were having below knee superficial varicosities and treated by 1% POL Sclerotherapy on outpatient basis.
All Patients were evaluated on the day, at first day post foam sclerotherapy and after 4 weeks after sclerotherapy. Patients developing skin necrosis in follow up were managed by skin grafting later.
In group A (STD) out of 20 patients' pain, hyperpigmentation and skin necrosis was present in n1=18 patients, n2=14 patients and in n3=02 patients respectively on the first post-operative day while in group B (POL) out of 24 patients it was in n1=14, n2=08 and n3=01 patient respectively. Post sclerotherapy after 4 weeks, in Group A pain and hyperpigmentation were present in n1=08 and n2=04 patients respectively but skin necrosis was persisting in all n3=2 patients. In-group B pain and hyperpigmentation were present in n1=02 patients only and skin necrosis was persisting in that patient (Figure 4) . DVT, allergy, visual disturbances, headache and chest tightness were absent in both groups.
DISCUSSION
Common adverse events after sclerotherapy are hyperpigmentation, which occurs due to migration of melanin in skin and deposition of hemosiderin due to extravasation of RBC along the course of vein and is found in 10-30%. It usually resolves in 6-12 month. Post sclerotherapy neovascularization (telangiectasia) occurs in 15-20% patients in area of sclerotherapy. Nerve injury i.e. saphenous nerve or sural nerve injury, adjacent to varicose vein occurs, which normally resolves in 3-6 months.
Superficial thrombophlebitis occurs in 4-7.5% characterized by erythema, tenderness and thrombosed vein. Cutaneous necrosis occurs in 0.23% due to extravasation or due to vasospasm or it may be due to leaking of sclerosant agent into capillary or artery. Other adverse events are transient ischemic attack, visual disturbances (1.4-14%), DVT (0.1%-6%) and cardiac toxicity. 9 In a study for treatment of VV by sclerosant, Subbarao et al. found that 70-80% of patients showed symptomatic improvement along with disappearance of veins and healing of eczema and ulcers. Most of the complications were minor, which resolved over a period of few weeks. 10 There is evidence that 3% polidocanol foam is no more effective than 1% polidocanol foam. The optimum ratio of gas to liquid is 4:1, although a range of ratios is reported in the published work.
There is a wide variation in the volume used as well as the method by which it is injected. The use of carbon dioxide foam reduces the systemic complications, particularly visual disturbance, as compared with air foams. 11 We used room air for foam sclerotherapy 1% in all patients. In a study of total 100 women patients with telangiectasias and small varicose veins of less than 4 mm were randomized for foam or liquid sclerotherapy and authors concluded that complete disappearance was determined in 84% of patients in the foam form group and in 72% in the liquid form group.
Although polidocanol in foam form's success rate was higher than the liquid form of polidocanol to clear the vessels, this result did not reach statistical significance (p=0.148). 12 VDs following sclerotherapy for varicose veins are rare and all reported events were transient. Bubble embolism or any kind of embolism seems unlikely to be the only underlying mechanism. 13 In a systemic review of 500 patients, no persistent visual disorders disturbances (VD) were reported.
VD has been reported to occur with polidocanol and sodium tetra-decyl sulphate in different concentrations (0.25-3%). Various forms of foam preparation including various ways of foam production and the liquid -air ratio (1 or 2 parts of liquid mixed with 3, 4 or 5 parts of air) were reported in association with the occurrence of VD. We did not find any patient having VD in either of the group. Rare complication like alopecia areata and anaphylactic shock following STD has been reported in literature post sclerotherapy. 14, 15 In a study reporting glycerin as a sclerosant, it was shown comparable to STD in discomfort of injection but demonstrated a significant decrease in bruising, swelling, and post procedural hyperpigmentation. Glycerin also demonstrated a better, more rapid clearance of treated telangiectasia. 16 In a comparative study by Goldman et al of POL versus STD as sclerosant for patients having competent SFJ and varicose vein divided into three categories on basis of size (<1 mm, 1-3 mm, 3-6 mm). Each leg was randomly treated with 0.25%, 0.5%, or 1.5% of STS or 0.5%, 1.0%, or 3% of Polidocanol respective of size. In this study an independent, three-panel, blindly randomized photographic examination was obtained pretreatment and at 4 and 16 weeks. All patients had an average of 70% improvement and were 70-72% satisfied in all vein
